Patents Issued in July 2, 2019
  • Patent number: 10336802
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 2, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
  • Patent number: 10336803
    Abstract: This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: July 2, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Horng H. Chen, John C. Burnett, Jr.
  • Patent number: 10336804
    Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: July 2, 2019
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Tong Zhang, Charles L. Sentman
  • Patent number: 10336805
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 2, 2019
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 10336806
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 2, 2019
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 10336807
    Abstract: The present disclosure provides systems for immune cell regulation and methods of immunotherapy. Systems of the present disclosure for immune cell regulation comprise a chimeric receptor polypeptide, a chimeric adaptor polypeptide, a gene modulating polypeptide (GMP), and a cleavage moiety.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: July 2, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lei S. Qi, Bing C Wang
  • Patent number: 10336808
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: July 2, 2019
    Assignee: Dako Denmark A/S
    Inventors: Jøgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 10336809
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 2, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10336810
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and/or a CD3? intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 2, 2019
    Assignees: University Health Network, Takara Bio Inc.
    Inventors: Shinya Tanaka, Naoto Hirano, Yuki Kagoya
  • Patent number: 10336811
    Abstract: The disclosure relates to a recombinant membrane span protein complex, comprising (1) a fusion protein, comprising a membrane span protein fused to a kinase domain, preferably a constitutive kinase and (2) a reporter construct comprising a polypeptide, interacting with the membrane span protein, fused to a reporter phosphorylation domain. The disclosure relates further to the uses of such membrane span protein complex for the detection of compounds that interact with the membrane span protein and for the screening and/or detection of inhibitors of the compound-membrane span protein interactions. In a preferred embodiment, the membrane span protein is a G protein coupled receptor (GPCR) and the method is used for the screening and/or detection of inhibitors of the ligand-receptor binding.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: July 2, 2019
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Samuel Lievens
  • Patent number: 10336812
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: July 2, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina Rangwala, Shannon Mullican, Jose Antonio Chavez
  • Patent number: 10336813
    Abstract: Disclosed is a fusion protein Slit2D2-HSA formed by fusion of a Slit2D2 polypeptide and a human serum albumin HSA, and use thereof for the manufacture of a medicament for prophylaxis and/or treatment of sepsis, and the said fusion protein Slit2D2-HSA retains the pharmacological activities of Slit2 in inhibition of neutrophil migration and treatment of sepsis, and has an improved stability, prolonged half-life and improved therapeutic effect of sepsis. Compared with protein of Slit2, the polypeptide of Slit2D2 has a smaller molecular weight which is much easier to be purified and separated in preparation and used in the development of drugs.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: July 2, 2019
    Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
    Inventor: Huashun Li
  • Patent number: 10336814
    Abstract: A collagen material having a form of thin fibrils generally free of fibril-bundling proteogylcan interactions, and a method for providing the thin fibril collagen material from native collagen fibers. The method uses proteoglycan antibodies to disassociate the proteoglycan interactions in bundled collagen fibrils to provide the constituent fibrils. The process can be used as a model for arthritis and the resulting fibrils can be used to form new extracellular matrix biomaterials and new tissues.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: July 2, 2019
    Assignee: MATRIX ODYSSEY, LLC
    Inventors: Joseph Orgel, Olga Antipova
  • Patent number: 10336815
    Abstract: Disclosed herein are phage-displayed single-chain variable fragment (scFv) libraries, which comprised a plurality of scFvs with a specific sequence in each CDR. The present scFv libraries could be used to efficiently produce different antibodies with high binding affinity to H1 hemagglutinin of influenza virus. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 2, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Ing-Chien Chen, Chao-Ping Tung, Chung-Ming Yu
  • Patent number: 10336816
    Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: July 2, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Hong-Sen Chen, Ing-Chien Chen, Chao-Ping Tung, Shin-Chen Hou, Chung-Ming Yu, Chi-Kai Yang, Yi-Kai Chiu
  • Patent number: 10336817
    Abstract: A therapeutic composition of camel milk can include an herbal composition having solid material or liquid extracts from the solid material of at least one of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The solid material may include one or more of parts or the whole of the stem, the bark, the flowers and the roots of one or more, but preferably all of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The therapeutic composition can include camel milk, alone, or in combination with the herbal composition. The camel milk can be HIV-immunized camel milk. The HIV-immunized camel milk can be obtained by immunizing a camel against HIV by administering to the camel the modified DNA plasmids of SEQ. ID No.: 3 and SEQ ID No.: 4 and obtaining the milk from the immunized camel.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: July 2, 2019
    Assignee: Sultan Qaboos University
    Inventors: Sidgi Syed Anwer Abdo Hasson, Ali A. H. Al-Jabri
  • Patent number: 10336818
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 2, 2019
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 10336819
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: July 2, 2019
    Assignees: Genentech, Inc., AC Immune SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Patent number: 10336820
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 2, 2019
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Jonathan Daniel Oliner, Eunkyung Lee
  • Patent number: 10336821
    Abstract: A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: July 2, 2019
    Assignees: CSL Limited, B-Creative Sweden AB
    Inventors: Ulf Eriksson, Ingrid Nilsson, Daniel Lawrence, Enming Joe Su
  • Patent number: 10336822
    Abstract: This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: July 2, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Vesna D. Garovic
  • Patent number: 10336823
    Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: July 2, 2019
    Assignee: MedImmune Limited
    Inventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
  • Patent number: 10336824
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: July 2, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • Patent number: 10336825
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: July 2, 2019
    Assignee: HANALL BIOPHARMA CO., LTD.
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Patent number: 10336826
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • Patent number: 10336827
    Abstract: Compositions and methods that utilize anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin ?V antibodies, anti-integrin ?1 antibodies, Abciximab, neutrophil inhibitory factor (NIF) protein, and/or combinations thereof to treat solid tumors are described.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 2, 2019
    Assignee: Wayne State University
    Inventor: Ghassan M. Saed
  • Patent number: 10336828
    Abstract: A fusion polynucleotide including a murine CMV promoter and an intron, a recombinant vector including the fusion polynucleotide and a gene encoding a polypeptide of interest, a recombinant cell including the recombinant vector, and a method of producing a polypeptide of interest using the recombinant vector and/or the recombinant cell.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: July 2, 2019
    Assignee: SAMSUNG BIOEPIS CO., LTD.
    Inventors: Su Jeong Hwang, Min-Kyung Kim, Sangjoon Park, Chanmoo Lee, Mi Young Cho
  • Patent number: 10336829
    Abstract: Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: July 2, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar Jörg Floris Kaufmann, Heehyoung Lee, Ingale Sampat Lalaso
  • Patent number: 10336830
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: July 2, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10336831
    Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: July 2, 2019
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventor: Charles P. Theuer
  • Patent number: 10336832
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: July 2, 2019
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Patent number: 10336833
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 2, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 10336834
    Abstract: A monoclonal antibody that binds to a phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: July 2, 2019
    Assignee: SBI Biotech Co., Ltd.
    Inventors: Minkwon Cho, Tomohide Yamazaki, Mayuki Endo, Koji Ishida
  • Patent number: 10336835
    Abstract: The present invention provides a crystalline form of Suagmmadex sodium, characterized by an X-ray powder diffraction pattern. The present invention further provides crystalline forms of Suagmmadex sodium for use in the manufacture of a pharmaceutical composition or a medicament. The present invention further provides a pharmaceutical composition comprising the crystalline form of Sugammadex sodium of the present invention and at least one pharmaceutical acceptable excipient.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: July 2, 2019
    Assignee: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • Patent number: 10336836
    Abstract: An object of the present invention is to provide a photocurable resin composition that has excellent adhesion to plastic substrates and can form a composition with good compatibility.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: July 2, 2019
    Assignee: Osaka Soda Co., Ltd.
    Inventors: Katsutoshi Yokoyama, Shinichiro Ohashi, Masahiro Kohara, Satoshi Inoue
  • Patent number: 10336837
    Abstract: [Problem to be solved] There is provided a process for producing an olefin polymer that is capable of producing an olefin polymer having high heat resistance and high molecular weight with excellent catalytic activity. [Solution to problem] The process for producing an olefin polymer includes a step of polymerizing at least one olefin selected from ethylene and ?-olefins having 4 to 30 carbon atoms in the presence of an olefin polymerization catalyst containing a transition metal compound represented by the general formula [I], the olefin polymer including constituent units derived from ethylene and ?-olefins having 4 to 30 carbon atoms in a total amount between more than 50 mol % and not more than 100 mol %, [in the formula [I], R1, R3 and R5 to R16 are each independently a hydrogen atom, a hydrocarbon group or the like; R2 is a hydrocarbon group or the like; R4 is a hydrogen atom; M is a transition metal of Group IV; Q is a halogen atom or the like; and j is an integer of 1 to 4].
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 2, 2019
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Munehito Funaya, Atsushi Sakuma, Ikuko Ebisawa, Shinsuke Kinoshita, Akiko Matsumoto, Hirokazu Tanaka, Shinya Tanaka
  • Patent number: 10336838
    Abstract: [Problem to be solved] There is provided a process for producing an olefin polymer that is capable of producing an olefin polymer having high heat resistance and high molecular weight with excellent catalytic activity. [Solution to problem] The process for producing an olefin polymer includes a step of polymerizing at least one olefin selected from ethylene and ?-olefins having 4 to 30 carbon atoms in the presence of an olefin polymerization catalyst containing a transition metal compound represented by the general formula [I], the olefin polymer including constituent units derived from ethylene and ?-olefins having 4 to 30 carbon atoms in a total amount between more than 50 mol % and not more than 100 mol %, [in the formula [I], R1, R3 and R5 to R16 are each independently a hydrogen atom, a hydrocarbon group or the like; R2 is a hydrocarbon group or the like; R4 is a hydrogen atom; M is a transition metal of Group IV; Q is a halogen atom or the like; and j is an integer of 1 to 4].
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 2, 2019
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Munehito Funaya, Atsushi Sakuma, Ikuko Ebisawa, Shinsuke Kinoshita, Akiko Matsumoto, Hirokazu Tanaka, Shinya Tanaka
  • Patent number: 10336839
    Abstract: A low viscosity polymer having a linear or branched backbone derived from farnesene monomers and at least one terminal-end functionalized with a hydroxyl group. This polymer may be further hydrogenated to reduce unsaturation and acrylated, such that it may be incorporated into a LOCA composition. The LOCA composition may be used in a laminated screen assembly, such as a touch screen, for electronic devices by adhering the LOCA composition between an optically transparent layer, such as a cover glass, and a display. The cured LOCA composition has a refractive index similar to the optically transparent layer. A method of making the low viscosity polymer for the LOCA composition includes anionically polymerizing farnesene monomers, quenching a living end of the polymer to provide the hydroxyl-terminated polymer; hydrogenating the hydroxyl-terminated polymer; and reacting the at least partially saturated hydroxyl-terminated polymer with at least one reagent to provide an acrylate terminated hydrogenated polymer.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: July 2, 2019
    Assignee: FINA TECHNOLOGY, INC.
    Inventors: Taejun Yoo, Herbert Chao, Steven K Henning
  • Patent number: 10336840
    Abstract: A composition is provided which comprises a propylene ethylene random copolymer having a melt flow rate (MFR) (as determined according to ASTM D1238, 230° C., 2.16 Kg) of less than 1 g/10 min, a xylene solubles content of less than 7% by weight, an ethylene content of from 3 to 5 percent by weight of the copolymer, and a value equal to or greater than 92 for the product of the Koenig B value times the % mm triads measured on the xylene insoluble fraction of the random copolymer obtained by the wet method. Pipes made from the composition demonstrate improved pressure endurance.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: July 2, 2019
    Assignee: W. R. Grace & Co.-Conn.
    Inventors: Chai-Jing Chou, Daniel W. Baugh, III, John Kaarto, Jan W. Van Egmond, Jeffrey D. Goad, William G. Sheard
  • Patent number: 10336841
    Abstract: In some embodiments provided herein is a self-supported phosphinimine single site catalyst having a molar ratio of Al from the activator (MAO) to the active metal in the catalyst from 5:1 to 30:1. The catalyst is prepared by precipitating an emulsion of the activated catalyst from a perfluoroalkane continuous phase resulting in spherical catalyst particles having a diameter typically from 5 to 200 ?m.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: July 2, 2019
    Assignee: NOVA Chemicals (International) S.A.
    Inventors: Qinyan Wang, Savini Udara Suduweli Kondage, Bradley Wade Funk, Amy Marie Baltimore
  • Patent number: 10336842
    Abstract: The present disclosure provides a novel transition metal compound having excellent structural stability together with polymerization reactivity, and thereby is useful as a catalyst in preparing an olefin-based polymer, particularly, a high molecular weight and low density olefin-based polymer, and a catalyst composition including the same.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 2, 2019
    Assignee: LG CHEM, LTD.
    Inventors: Yoon Hee Cho, Jin Sam Gong, Jung Ho Jun, Choong Hoon Lee, Seung Hwan Jung
  • Patent number: 10336843
    Abstract: An ultra-high molecular weight ethylene-based copolymer powder comprising: an ethylene unit and an ?-olefin unit having 3 or more and 8 or less carbon atoms as structural units, wherein the ultra-high molecular weight ethylene-based copolymer powder has a viscosity-average molecular weight of 100,000 or more and 10,000,000 or less, a content of the ?-olefin unit is 0.01 mol % or more and 0.10 mol % or less based on a total amount of the ethylene unit and the ?-olefin unit, and in measurement with a differential scanning calorimeter under following conditions, an isothermal crystallization time is determined as a time from reaching 126° C. of Step A3 as a starting point (0 min) to giving an exothermic peak top due to crystallization and the isothermal crystallization time is 5 minutes or more. (Conditions for measurement of isothermal crystallization time) Step A1: holding at 50° C. for 1 minute and then an increase up to 180° C. at a temperature rise rate of 10° C./min, Step A2: holding at 180° C.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: July 2, 2019
    Assignee: Asahi Kasei Kabushiki Kaisha
    Inventor: Yoshiaki Hamada
  • Patent number: 10336844
    Abstract: Provided is a method of preparing a powdery diacetal clarifying agent, which comprises mixing an aromatic aldehyde, a polyol, and an acid catalyst in an organic polar solvent, adding a hydrogenating agent and an inorganic silicon-containing agent into the foregoing mixture, and filtering the mixture. The powdery diacetal clarifying agent prepared by the method can have excellent flowability, dispersability, thermal resistance, and color stability. Accordingly, the powdery diacetal clarifying agent does not release stinking odor and incur yellowing at high temperature, allowing the plastic articles to have improved appearance and visual appeal.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: July 2, 2019
    Assignee: SUNKO INK CO., LTD.
    Inventors: Chiu-Peng Tsou, Ting-Ti Huang, Chen-Ku Hsieh, Tien-Chu Chang, Ming-Chang Hsieh
  • Patent number: 10336845
    Abstract: A propylene-ethylene-diene terpolymer and method of making such comprising from 2% to 25% wt % by weight of ethylene, from 98% to 75% wt % by weight propylene and from 1% to 21% wt % by weight of a diene, wherein the terpolymer has a crystallinity of less than 3%, a melt flow rate (MFR) of less than 10 and a Tg by DSC of from ?2° C. to ?25° C. and methods to prepare the terpolymer are depicted.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: July 2, 2019
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Andy H. Tsou, Edward J. Blok, Gabor Kiss, Rhutesh K. Shah
  • Patent number: 10336846
    Abstract: The invention provides a process to form an ethylene/a-olefin interpolymer, comprising at least the following steps A) through C): A) polymerizing, in at least one reactor, at least one reaction mixture comprising ethylene and the a-olefin, in a solution polymerization, and in the presence of at least the following components I), II) and III): I) at least one compound of Structure 1, as described herein; II) at least one co-catalyst, as described herein; III) at least one compound of Structure 2, as described herein; B) separating the final polymer solution into at least a polymer-rich solution and a polymer-free solution; and optionally, at least a portion of the polymer-free solution is recycled back to the reactor; C) maintaining the level of the at least one compound of Structure 2 in the at least one reactor, from 100 ppm to 10,000 ppm, as described herein.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: July 2, 2019
    Assignee: Dow Global Technologies LLC
    Inventors: Sean W. Ewart, Susan G. Brown, Daniela Ferrari, Edward O. Madenjian, Gregory J. Brennan
  • Patent number: 10336847
    Abstract: The present invention relates to a vinyl chloride-based polymer containing an unsaturated fatty acid ester at a specific ratio, a method for preparing the same, a thermoplastic resin composition containing the same, and a thermoplastic resin molded article produced from the composition. The vinyl chloride-based polymer may have good processability, and thus, the thermoplastic resin molded article produced from the thermoplastic resin composition containing the vinyl chloride-based polymer may have high impact strength and improved appearance characteristics.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: July 2, 2019
    Assignee: LG CHEM, LTD.
    Inventors: Seong Yong Ahn, Kun Ji Ki, Se Woong Lee, Seong Jae Shin
  • Patent number: 10336848
    Abstract: The present invention relates to multi-arm surfactant-system thickening star macromolecules, and methods of preparing and using the same. In one aspect of the invention, a surfactant-system thickening star macromolecule is capable of providing surfactant-compatibility, increase the viscosity of a surfactant-containing system, and/or temperature-stability to an aqueous composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 2, 2019
    Assignee: Pilot Polymer Technologies, Inc.
    Inventors: Liang Huang, Yuanxi Liao, Patrick McCarthy
  • Patent number: 10336849
    Abstract: The present application relates to novel copolymers and processes for the preparation thereof, where the copolymers comprise, as building blocks: a C1-20-alkyl (meth)acrylate and/or C8-20-vinylaromatics (monomer a); a monoethylenically unsaturated, hydrophilic monomer comprising at least one sulfonic acid group (—SO3M) (monomer b); and a monoethylenically unsaturated monomer comprising at least one oxazoline group (monomer c); and where the fraction of the monomers a) and b) is in total less than 50% by weight, based on the total amount of the monomers in the copolymer A.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: July 2, 2019
    Assignee: BASF SE
    Inventors: Matthias Zorn, Yvonne Dieckmann, Iris Peters-Steuer, Kathrin Michl
  • Patent number: 10336850
    Abstract: A method comprising introducing a treatment fluid into a subterranean formation, wherein the treatment fluid comprises a base fluid and a crosslinked polymer, the crosslinked polymer comprising reactants of a first repeating unit, a second repeating unit, and a crosslinker that react to form the crosslinked polymer, wherein the first repeating unit is a sulfonic acid-containing monomer present from 50% to 99% by weight of the reactants, wherein the second repeating unit selected from the group consisting of an N-vinyl amide-containing monomer, a terminal double bond-containing monomer, and any combination thereof, and is present from 1% to 50% by weight of the reactants, and wherein the crosslinker comprises at least two olefinic bonds.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: July 2, 2019
    Assignee: Hallibunon Energy Services, Inc.
    Inventors: Weibin Zha, Kay A. Galindo, Hui Zhou
  • Patent number: 10336851
    Abstract: A copolymer for lithography having a turbidity Th(80) of 1.0 NTU or more and 4.6 NTU or less and a turbidity Tm(80) of 1.0 NTU or more and 3.8 NTU or less, in which this turbidity Th(80) is a turbidity of a PGMEA solution when n-heptane in an amount to be 80% of (X)h is added to this PGMEA solution where (X)h denotes an amount of n-heptane added to have a turbidity of 10 NTU when n-heptane is added to the PGMEA solution containing this copolymer for lithography at 20 wt % with respect to a total mass of this PGMEA solution; and this turbidity Tm(80) is a turbidity of a PGMEA solution when methanol in an amount to be 80% of (X)m is added to this PGMEA solution where (X)m denotes an amount of methanol added to have a turbidity of 5.0 NTU when methanol is added to this PGMEA solution containing this copolymer for lithography at 20 wt % with respect to a total mass of this PGMEA solution.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: July 2, 2019
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Atsushi Yasuda, Miho Chujo